Physician profile
Ilmana Fulger
NPI 1265559199
$11,244.04
in general payments reported to CMS, 2019-2025
52 companies · $3,608 in 2025
The $3,608 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $517 · 2021: $289 · 2022: $568 · 2023: $1,963 · 2024: $3,339 · 2025: $3,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,524 · Long Term Medical Supply Or Device Loan: $781 · Education: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,524.34 |
| Long Term Medical Supply Or Device Loan | $781.23 |
| Education | $604.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,054.89 | 2019-2025 | |
| Janssen Biotech, INC. | $1,244.53 | 2019-2025 | Erleada, Balversa, Tecvayli |
| Pfizer INC. | $885.55 | 2019-2025 | |
| Daiichi Sankyo INC. | $646.78 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Astrazeneca Pharmaceuticals Lp | $613.59 | 2019-2025 | Imfinzi, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $532.09 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Gilead Sciences, INC. | $510.42 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $450.14 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $306.81 | 2019-2025 | Opdivo |
| Celgene Corporation | $294.35 | 2021-2025 | Pomalyst, Reblozyl |
| Eisai INC. | $285.01 | 2023-2025 | |
| Glaxosmithkline, LLC. | $240.86 | 2024-2025 | Jemperli, Ojjaara |
| Incyte Corporation | $235.28 | 2020-2025 | Jakafi, Monjuvi, Zynyz |
| Stemline Therapeutics INC. | $221.26 | 2024-2025 | Orserdu |
| Seagen INC. | $211.82 | 2019-2025 | Adcetris |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilmana Fulger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.